Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Moodys
McKinsey
Express Scripts
Mallinckrodt

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,573,293

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,573,293 protect, and when does it expire?

Patent 6,573,293 protects SUTENT and is included in one NDA.

Protection for SUTENT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-four patent family members in forty-one countries.

Summary for Patent: 6,573,293
Title: Pyrrole substituted 2-indolinone protein kinase inhibitors
Abstract:The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
Inventor(s): Tang; Peng Cho (Moraga, CA), Miller; Todd A. (Bend, OR), Li; Xiaoyuan (Los Altos, CA), Sun; Li (Foster City, CA), Wei; Chung Chen (Foster City, CA), Shirazian; Shahrzad (Corte Madera, CA), Liang; Congxin (Sunnyvale, CA), Vojkovsky; Tomas (San Francisco, CA), Nematalla; Asaad S. (Concord, CA), Hawley; Michael (Kalamazoo, MI)
Assignee: Sugen, Inc. (South San Francisco, CA) Pharmacia & Upjohn Co. (Kalamazoo, MI)
Application Number:09/783,264
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,573,293
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,573,293

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-001 Jan 26, 2006 RX Yes No   Start Trial   Start Trial Y   Start Trial
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-002 Jan 26, 2006 RX Yes No   Start Trial   Start Trial Y   Start Trial
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-004 Mar 31, 2009 RX Yes No   Start Trial   Start Trial Y   Start Trial
Cppi Cv SUTENT sunitinib malate CAPSULE;ORAL 021938-003 Jan 26, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
McKesson
AstraZeneca
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.